Low-grade intestinal inflammation plays a key role in the pathophysiology of visceral pain [53], and gut microbiota can induce gut inflammation by triggering chronic release of pro-inflammatory mediators from the host such as prostaglandin 2, histamine, and cytokines including IL-1, IL-6, IL-8, IL-10, and TNF- [54, 55]
In this cohort, subcutaneous injection ( n = 141, 93%) was the primary route of exposure, followed by ingestion of oral tablets ( n = 10, 7%)
The daily tablet is a different branded formulation with its own dosing
Billington, C
Front Endocrinol (Lausanne) 13:1006376 Deepa Maheshvare M, Raha S, Knig M, Pal D
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions